MyFinsight
Home
Blog
About
Contact
Download
Download image
Stock-based compensation
$71,424K
Proceeds from issuance of
common stock pursuant...
$40,142K
Accounts payable,
accrued expenses and...
$50,103K
Depreciation and
amortization
$24,244K
Inventory reserves and
firm commitment...
-$2,889K
Amortization of debt discount
and offering costs
$1,739K
Non-cash lease expense
$1,730K
Net cash provided by
(used in) operating...
$55,827K
Net cash provided by
financing activities
$40,142K
Canceled cashflow
$96,302K
Effect of exchange rate
on cash, cash...
$3,222K
Net increase
(decrease) in cash, cash...
$75,237K
Canceled cashflow
$23,954K
Accounts receivable
$48,055K
Net loss
-$23,363K
Inventory
$8,448K
Prepaid and other
current assets
$5,756K
Other assets
$5,663K
Operating lease
liabilities
-$1,896K
Unrealized foreign
exchange (gain) loss
$1,720K
Other
$1,401K
Proceeds from maturities
of investments
$74,425K
Net cash used in
investing activities
-$23,954K
Canceled cashflow
$74,425K
Purchase of investments
$97,425K
Purchase of property and
equipment
$954K
Back
Back
Cash Flow
source: myfinsight.com
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)